Achievement of 50% MMD reduction over months 4 to 6 showed a nominally significant improvement in the erenumab, 140 mg, group (109 [56.2%]) and 70 mg group (81 [41.8%]) relative to placebo (51 [26.3%]) (eTable 12 in Supplement 1 ).
← all excerpts
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial.
1
—
—